NCT03040973 2026-04-02Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment AloneNovartisPhase 2 Active not recruiting29 enrolled
NCT02411448 2026-01-16RELAYEli Lilly and CompanyPhase 3 Active not recruiting545 enrolled 24 charts 2 FDA
NCT03333343 2026-01-16Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCNovartisPhase 1 Active not recruiting105 enrolled